News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
264,468 Results
Type
Article (14099)
Company Profile (282)
Press Release (250087)
Section
Business (79454)
Career Advice (152)
Deals (13218)
Drug Delivery (35)
Drug Development (50397)
Employer Resources (31)
FDA (5702)
Job Trends (5125)
News (144288)
Policy (10024)
Tag
Academia (905)
Alliances (21605)
Alzheimer's disease (796)
Antibody-drug conjugate (ADC) (75)
Approvals (5704)
Artificial intelligence (93)
Bankruptcy (102)
Best Places to Work (4561)
Biotechnology (232)
Breast cancer (130)
Cancer (1112)
Cardiovascular disease (88)
Career advice (132)
CAR-T (92)
Cell therapy (272)
Clinical research (40556)
Collaboration (436)
Compensation (184)
COVID-19 (1024)
C-suite (117)
Cystic fibrosis (74)
Data (1150)
Diabetes (105)
Diagnostics (1278)
Earnings (29210)
Events (47650)
Executive appointments (353)
FDA (6208)
Funding (414)
Gene editing (76)
Gene therapy (199)
GLP-1 (338)
Government (1071)
Healthcare (6568)
Infectious disease (1075)
Inflammatory bowel disease (105)
IPO (7247)
Job creations (859)
Job search strategy (127)
Layoffs (196)
Legal (1383)
Lung cancer (164)
Manufacturing (103)
Medical device (2576)
Medtech (2577)
Mergers & acquisitions (6205)
Metabolic disorders (315)
Neuroscience (1108)
NextGen: Class of 2025 (2012)
Non-profit (852)
Northern California (1339)
Obesity (166)
Opinion (96)
Parkinson's disease (89)
Patents (86)
People (25352)
Phase I (14313)
Phase II (18872)
Phase III (11921)
Pipeline (504)
Postmarket research (852)
Preclinical (5996)
Radiopharmaceuticals (209)
Rare diseases (248)
Real estate (1414)
Regulatory (8438)
Research institute (932)
Series A (82)
Southern California (1188)
Startups (1968)
United States (10528)
Vaccines (189)
Weight loss (96)
Date
Today (48)
Last 7 days (334)
Last 30 days (1537)
Last 365 days (20410)
2025 (2640)
2024 (20552)
2023 (22417)
2022 (26822)
2021 (27806)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13747)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Asia (17095)
Australia (2893)
California (3047)
Canada (965)
China (269)
Colorado (115)
Connecticut (130)
Delaware (72)
Europe (36776)
Florida (348)
Georgia (91)
Illinois (192)
Indiana (73)
Maryland (396)
Massachusetts (2383)
Minnesota (119)
New Jersey (761)
New York (835)
North Carolina (475)
Northern California (1339)
Ohio (98)
Pennsylvania (576)
South America (207)
Southern California (1188)
Texas (337)
Washington State (291)
264,468 Results for "akcea therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Deals
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the successful completion of its transaction to acquire 100% ownership of Akcea Therapeutics, Inc. (NASDAQ: AKCA). The combination of Ionis and Akcea accelerates the next phase of Ionis’ gr
October 12, 2020
·
5 min read
Deals
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash
August 31, 2020
·
10 min read
Drug Development
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs).
November 3, 2020
·
6 min read
Press Releases
Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences
February 20, 2025
·
1 min read
Press Releases
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
February 20, 2025
·
1 min read
Press Releases
Allogene Therapeutics Announces Participation in February Investor Conferences
February 4, 2025
·
2 min read
Press Releases
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
January 30, 2025
·
4 min read
Drug Development
Akcea Retains Rights to AKCEA-APOCIII-LRxData from Phase 2 clinical trial of AKCEA-APOCIII-LRx anticipated in early 2020
Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc., announced that, following a strategic portfolio decision by Novartis not to exercise its option, Akcea has retained rights to develop and commercialize AKCEA-APOCIII-LRx.
December 18, 2019
·
6 min read
Business
Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast
Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time to discuss its second quarter 2020 financial results and report on pipeline and business progress.
July 21, 2020
·
3 min read
1 of 26,447
Next
